Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice

Autor: Yuen Yin Lee, Victor Grijalva, Xiaoyan Wang, Asokan Devarajan, Jennifer Wang, Diana M. Shih, Christy Montano, Ernest Brahn, Ani Shahbazian, Aldons J. Lusis, Srinivasa T. Reddy, Christina Charles-Schoeman
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Aging
Inflammatory arthritis
Gene Expression
Arthritis
Cardiovascular
Transgenic
Arthritis
Rheumatoid

Pathogenesis
Mice
0302 clinical medicine
Rheumatoid
2.1 Biological and endogenous factors
Molecular Targeted Therapy
Transgenes
Aetiology
Multidisciplinary
biology
Glutathione
PON1
Liver
Rheumatoid arthritis
Medicine
Biotechnology
Signal Transduction
Genetically modified mouse
medicine.medical_specialty
Transgene
Science
Cardiology
Rheumatoid Arthritis
Mice
Transgenic

Autoimmune Disease
Article
03 medical and health sciences
Rheumatology
Internal medicine
Genetics
medicine
Animals
Humans
Dyslipidemias
Inflammation
030203 arthritis & rheumatology
Aryldialkylphosphatase
business.industry
Inflammatory and immune system
Paraoxonase
Atherosclerosis
medicine.disease
030104 developmental biology
Endocrinology
Chronic Disease
biology.protein
business
Zdroj: Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Scientific Reports
Scientific reports, vol 10, iss 1
ISSN: 2045-2322
Popis: Paraoxonase 1(PON1) is an HDL-associated protein, which metabolizes inflammatory, oxidized lipids associated with atherosclerotic plaque development. Because oxidized lipid mediators have also been implicated in the pathogenesis of rheumatoid arthritis (RA), we evaluated the role of PON1 in murine inflammatory arthritis. K/BxN serum transfer (STIA) or collagen antibody transfer (CAIA) was used for arthritis induction in B6 mice homozygous for the PON1 human transgene [PON1Tg], PON1 knock-out mice [PON1KO], and wild type littermate control mice [WT]. Experiments were also performed in K/BxN mice with chronic arthritis, and in RA patients and healthy controls. Arthritis activity in K/BxN mice was associated with a marked dyslipidemia, lower PON1 activity and higher bioactive lipid mediators (BLM), as well as a dysregulated hepatic lipid gene expression profile. Higher serum PON1 activity correlated with lower BLM and lower arthritis activity in both K/BxN mice and RA patients. Overexpression of the human PON1 transgene was associated with reduced inflammatory arthritis, which correlated strongly with higher circulating PON1 activity, upregulation of the hepatic glutathione pathway, and reduction of circulating BLM. These results implicate PON1 as a potential novel therapeutic target for joint disease in RA with potential for vascular benefit, which warrants further investigation.
Databáze: OpenAIRE
Nepřihlášeným uživatelům se plný text nezobrazuje